-
2 days ago | 
onclive.com | Ashling Wahner
The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancers (NSCLC) have added taletrectinib (Ibtrozi) as a preferred agent for the first-line and subsequent treatment of patients with advanced ROS1-positive NSCLC.1,2The guidelines also include recommendations for the use of taletrectinib—a highly selective, next-generation oral ROS1 TKI—in patients with brain metastases and resistance mutations.
-
3 days ago | 
onclive.com | Ashling Wahner
The neoadjuvant combination of pembrolizumab (Keytruda) with the TLR9 agonist vidutolimod (formerly CMP-001) generated higher pathologic complete response (pCR) rates vs pembrolizumab alone, as well as an acceptable safety profile, in patients with macroscopic, resectable stage III melanoma, according to Ahmad Tarhini, MD, PhD.
-
1 week ago | 
onclive.com | Ashling Wahner
Efficacy and safety data with the all-oral regimen of zanubrutinib (Brukinsa) and venetoclax (Venclexta) may redefine clinical practice by providing a safe and adaptable approach to first-line therapy for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to Mazyar Shadman, MD, MPH. The phase 3 SEQUOIA trial (NCT03336333) investigated zanubrutinib across several arms of patients with previously untreated CLL/SLL.
-
1 week ago | 
onclive.com | Ashling Wahner
The 2025 EHA Congress was filled with practice-informing data from across hematologic oncology subsets, ranging from studies on the brink of changing treatment standards to intriguing early-phase developments. During the meeting, experts provided OncLive® with their top takeaways.
-
1 week ago | 
onclive.com | Ashling Wahner
Emerging lung cancer data presented at the 2025 ASCO Annual Meeting signal a paradigm shift toward more targeted, synergistic treatment strategies, with trials such as the phase 3 DeLLphi-304 (NCT05740566) and CheckMate 816 (NCT02998528) studies demonstrating that strategically sequenced immunotherapy regimens may significantly improve survival outcomes, according to Miguel Gonzalez-Velez, MD.
-
1 week ago | 
onclive.com | Ashling Wahner
The combination of venetoclax (Venclexta) and azacitidine (Vidaza) did not provide an overall survival (OS) advantage over placebo plus azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (MDS), failing to meet the primary end point of the phase 3 VERONA trial (NCT04401748).1The hazard ratio for OS was 0.908 (stratified log-rank P = .3772). The investigators observed no new safety signals, according to a news release.
-
1 week ago | 
cgtlive.com | Matthew Ku |Noah Stansfield |Ashling Wahner |Chris Ryan
Data from a phase 1b clinical trial (NCT05421663) evaluating Johnson & Johnson’s JNJ-90014496, a CD19 and CD20-directed bispecific chimeric antigen receptor (CAR) T-cell therapy, were presented at the European Hematology Association (EHA) 2025 Congress, held June 12 to 15, both virtually and in Milan, Italy.
-
1 week ago | 
cgtlive.com | Saurabh Dahiya |Noah Stansfield |Ashling Wahner |Caroline Seymour
At the European Hematology Association (EHA) 2025 Congress, held June 12 to 15, both virtually and in Milan, Italy, Galapagos presented new data regarding GLPG5101, an investigational. CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy product. During the conference, CGTLive® interviewed Omotayo Fasan, MRCP, DTM&H, MBBS, the head of the clinical development program at Galapagos, about the findings.
-
1 week ago | 
cgtlive.com | Matthew Ku |Ashling Wahner |Chris Ryan
This video originally appeared on our sister site, OncLive®. "Overall, only 7 patients, or 28% of the recommended phase 2 dose group, reported a serious treatment emergent adverse event."Johnson & Johnson’s JNJ-90014496, a CD19 and CD20-directed bispecific chimeric antigen receptor (CAR) T-cell therapy, is currently being evaluated for the treatment of relapsed/refractory (r/r) large B-cell lymphoma (LBCL) in a phase 1b clinical trial (NCT05421663).
-
1 week ago | 
cgtlive.com | Saurabh Dahiya |Noah Stansfield |Ashling Wahner |Caroline Seymour
At the European Hematology Association (EHA) 2025 Congress, held June 12 to 15, both virtually and in Milan, Italy, data are being presented from a phase 1 clinical trial (NCT04989803) evaluating Kite's KITE-363, a dual CD19 and CD20-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients with relapsed/refractory (r/r) B-cell lymphoma.
